ATE404553T1 - Hochaffine kleinmolekülige c5a-rezeptor- modulatoren - Google Patents

Hochaffine kleinmolekülige c5a-rezeptor- modulatoren

Info

Publication number: ATE404553T1
Authority: AT; Austria
Prior art keywords: act; compounds; receptors; small molecule; complement
Prior art date: 2000-09-29

Application number

AT00965522T

Other languages

English (en)

Inventor

Andrew Thurkauf

Xiaoyan Zhang

Xia-Shu He

He Zhao

John Peterson

George Maynard

Robert Ohliger

Original Assignee

Neurogen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-29

Filing date

2000-09-29

Publication date

2008-08-15

2000-09-29 Application filed by Neurogen Corp filed Critical Neurogen Corp

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404553T1 publication Critical patent/ATE404553T1/de

Links

PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 title 1
150000003384 small molecules Chemical class 0.000 title 1
102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
108010078546 Complement C5a Proteins 0.000 abstract 2
239000003446 ligand Substances 0.000 abstract 2
108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000011268 leukocyte chemotaxis Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J1/00—Details of electrodes, of magnetic control means, of screens, or of the mounting or spacing thereof, common to two or more basic types of discharge tubes or lamps
- H01J1/02—Main electrodes
- H01J1/30—Cold cathodes, e.g. field-emissive cathode

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Neurology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Nanotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Crystallography & Structural Chemistry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Manufacturing & Machinery (AREA)

AT00965522T 2000-09-29 2000-09-29 Hochaffine kleinmolekülige c5a-rezeptor- modulatoren ATE404553T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2000/026816 WO2002049993A2 (en)	2000-09-29	2000-09-29	High affinity small molecule c5a receptor modulators

Publications (1)

Publication Number	Publication Date
ATE404553T1 true ATE404553T1 (de)	2008-08-15

Family

ID=21741822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00965522T ATE404553T1 (de)	2000-09-29	2000-09-29	Hochaffine kleinmolekülige c5a-rezeptor- modulatoren

Country Status (13)

Country	Link
EP (1)	EP1322309B1 (de)
JP (1)	JP5260818B2 (de)
KR (1)	KR20030060887A (de)
CN (1)	CN1454086A (de)
AT (1)	ATE404553T1 (de)
AU (1)	AU7622500A (de)
BR (1)	BR0017338A (de)
DE (1)	DE60039921D1 (de)
IL (1)	IL154993A0 (de)
MX (1)	MXPA03002788A (de)
NO (1)	NO20031370L (de)
WO (1)	WO2002049993A2 (de)
YU (1)	YU23503A (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8535601A1 (es)	2000-12-21	2002-11-28	Pfizer	Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US6858637B2 (en)	2002-03-28	2005-02-22	Neurogen Corporation	Substituted biaryl amides as C5a receptor modulators
AU2003218374A1 (en)	2002-03-28	2003-10-13	Neurogen Corporation	Substituted tetrahydroisoquinolines as c5a receptor modulators
EP1487796A4 (de) *	2002-03-28	2005-11-16	Neurogen Corp	Substituierte biarylamide als modulatoren des c5a-rezeptors
CA2480888A1 (en) *	2002-03-29	2003-10-09	Neurogen Corporation	New aryl imidazoles and related compounds as c5a receptor modulators
GB0214139D0 (en) *	2002-06-19	2002-07-31	Glaxo Group Ltd	Chemical compounds
WO2004018460A1 (en) *	2002-08-21	2004-03-04	Neurogen Corporation	Amino methyl imidazoles as c5a receptor modulators
CN100528846C (zh) *	2002-09-11	2009-08-19	株式会社吴羽	胺化合物及其用途
ATE552253T1 (de)	2002-11-08	2012-04-15	Novartis Int Pharm Ltd	3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
US8329169B2 (en)	2003-05-15	2012-12-11	Genentech, Inc.	Methods and compositions for the prevention and treatment of sepsis
US7932281B2 (en)	2004-03-10	2011-04-26	Kureha Corporation	Amine-based compound and use thereof
WO2006012373A2 (en) *	2004-07-20	2006-02-02	Critical Therapeutics, Inc.	Combination therapies of hmgb and complement inhibitors against inflammation
JP2007284352A (ja) *	2004-08-05	2007-11-01	Dai Ichi Seiyaku Co Ltd	ピラゾール誘導体
AR055287A1 (es)	2004-12-01	2007-08-15	Kalypsys Inc	Inhibidores de la dimerizacion de la sintasa inducible por oxido nitrico ,composiciones farmaceuticas
EP1856126A2 (de)	2005-02-17	2007-11-21	Wyeth a Corporation of the State of Delaware	Cycloalkyl-anelliertes indol, benzothiophen, benzofuran und inden-derivate
EP1739078A1 (de)	2005-05-30	2007-01-03	Jerini AG	C5a-Rezeptor-Antagonisten
CA2965223C (en)	2008-12-22	2019-09-24	Chemocentryx, Inc.	C5ar antagonists
PT2585064T (pt)	2010-06-24	2017-08-08	Chemocentryx Inc	Antagonistas do c5ar
AU2014257164B2 (en) *	2013-04-22	2018-10-11	Abbvie Inc.	Thiazoles and uses thereof
NZ730123A (en)	2014-09-29	2023-05-26	Chemocentryx Inc	Processes and intermediates in the preparation of c5ar antagonists
EP3072891A1 (de) *	2015-03-24	2016-09-28	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Neue Toll-ähnliche Rezeptor-9-Antagonisten
CN108601790B (zh)	2016-01-14	2026-01-27	凯莫森特里克斯股份有限公司	C3肾小球病的治疗方法
AU2017246228B2 (en)	2016-04-04	2021-04-15	Chemocentryx, Inc.	Soluble C5aR antagonists
WO2018222601A1 (en)	2017-05-31	2018-12-06	Chemocentryx, Inc.	5-5 FUSED RINGS AS C5a INHIBITORS
CN110997674B (zh)	2017-05-31	2022-12-20	凯莫森特里克斯股份有限公司	作为C5a抑制剂的6-5稠合环类
KR20200109298A (ko)	2017-10-30	2020-09-22	케모센트릭스, 인크.	면역조절제로서의 중수소화된 화합물
MX2020006460A (es)	2017-12-22	2020-11-06	Chemocentryx Inc	Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
ES2980175T3 (es)	2017-12-22	2024-09-30	Chemocentryx Inc	Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
WO2019195159A1 (en)	2018-04-02	2019-10-10	Chemocentryx, Inc.	PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
CN114957165A (zh) *	2021-02-26	2022-08-30	清华大学	一种抗病毒化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6157590A (ja) *	1984-08-29	1986-03-24	Asahi Shiyueebell Kk	シラン化合物およびその製造法
US5681956A (en) *	1990-12-28	1997-10-28	Neurogen Corporation	4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5159083A (en) *	1990-12-28	1992-10-27	Neurogen Corporation	Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands
MX9308025A (es) *	1992-12-22	1994-08-31	Lilly Co Eli	Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5652237A (en) *	1994-09-09	1997-07-29	Warner-Lambert Company	2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
AU4368996A (en) *	1994-11-23	1996-06-17	Neurogen Corporation	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
GB9426103D0 (en) *	1994-12-23	1995-02-22	Merck Sharp & Dohme	Therapeutic agents
ID19609A (id) *	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
EP1017382B1 (de) *	1997-05-29	2006-03-01	Merck & Co., Inc. (a New Jersey corp.)	Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
MY153569A (en) *	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
ES2255251T3 (es) *	1998-03-20	2006-06-16	Daiichi Asubio Pharma Co., Ltd.	Inhibidores de nf-kb que contienen derivados de benzoquinona.
ATE316961T1 (de) *	1998-05-22	2006-02-15	Scios Inc	Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
CN1309638A (zh) *	1998-07-10	2001-08-22	阿斯特拉曾尼卡有限公司	作为神经激肽受体拮抗剂的n－取代的萘甲酰胺
US6423519B1 (en) *	1998-07-15	2002-07-23	Gpc Biotech Inc.	Compositions and methods for inhibiting fungal growth
ID27787A (id) *	1998-08-21	2001-04-26	Viro Pharma Inc	Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
US6437146B1 (en) *	1998-09-25	2002-08-20	Fujisawa Pharmaceutical Co., Ltd.	Oxazole compounds as prostaglandin e2 agonists or antagonists
WO2000025780A1 (en) *	1998-10-29	2000-05-11	Bristol-Myers Squibb Company	Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6503905B1 (en) *	1998-12-29	2003-01-07	Pfizer Inc	3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
BR0010655A (pt) *	1999-03-24	2002-02-13	Anormed Inc	Compostos heterocìclicos para ligação ao receptor de quimiocina
US6369226B1 (en) *	1999-06-21	2002-04-09	Agouron Pharmaceuticals, Inc.	Substituted benzamide inhibitors of rhinovirus 3C protease
EP1218358B1 (de) *	1999-09-23	2006-09-13	AstraZeneca AB	Chinazoline verbindungen als heilmittel
PT1317451E (pt) *	2000-09-15	2006-12-29	Anormed Inc	Compostos heterocíclicos que se ligam a receptores de quimioquinas

2000
- 2000-09-29 EP EP00965522A patent/EP1322309B1/de not_active Expired - Lifetime
- 2000-09-29 AU AU7622500A patent/AU7622500A/xx active Pending
- 2000-09-29 YU YU23503A patent/YU23503A/sh unknown
- 2000-09-29 IL IL15499300A patent/IL154993A0/xx unknown
- 2000-09-29 AT AT00965522T patent/ATE404553T1/de not_active IP Right Cessation
- 2000-09-29 BR BR0017338-0A patent/BR0017338A/pt not_active IP Right Cessation
- 2000-09-29 KR KR10-2003-7003410A patent/KR20030060887A/ko not_active Ceased
- 2000-09-29 JP JP2002551496A patent/JP5260818B2/ja not_active Expired - Fee Related
- 2000-09-29 DE DE60039921T patent/DE60039921D1/de not_active Expired - Lifetime
- 2000-09-29 WO PCT/US2000/026816 patent/WO2002049993A2/en not_active Ceased
- 2000-09-29 CN CN00819935A patent/CN1454086A/zh active Pending
- 2000-09-29 MX MXPA03002788A patent/MXPA03002788A/es unknown
2003
- 2003-03-26 NO NO20031370A patent/NO20031370L/no unknown

Also Published As

Publication number	Publication date
NO20031370L (no)	2003-05-30
MXPA03002788A (es)	2004-12-13
WO2002049993A2 (en)	2002-06-27
CN1454086A (zh)	2003-11-05
WO2002049993A3 (en)	2003-02-20
DE60039921D1 (de)	2008-09-25
NO20031370D0 (no)	2003-03-26
EP1322309A4 (de)	2004-10-13
JP5260818B2 (ja)	2013-08-14
EP1322309A2 (de)	2003-07-02
BR0017338A (pt)	2004-04-27
KR20030060887A (ko)	2003-07-16
AU7622500A (en)	2002-07-01
IL154993A0 (en)	2003-10-31
YU23503A (sh)	2006-03-03
EP1322309B1 (de)	2008-08-13
JP2004525873A (ja)	2004-08-26

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE404553T1 (de)	2008-08-15	Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
EA200300441A1 (ru)	2003-08-28	Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
FR2732017B1 (fr)	2000-09-22	Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
CY1118849T1 (el)	2018-01-10	Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
IS8502A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MY137535A (en)	2009-02-27	New pyrrolidinium derivatives
ATE293995T1 (de)	2005-05-15	Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
IS6658A (is)	2002-12-17	Ný efnasambönd
SE9902987D0 (sv)	1999-08-24	Novel compounds
GEP20063741B (en)	2006-02-10	Nonaryl-Heterocyclic NMDA/NR2B Antagonists
TR200400295T2 (tr)	2005-04-21	Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi
BRPI0418112A (pt)	2007-04-17	inibidores de p-38 quinase bicìclico heterocìclicos
CY1112362T1 (el)	2015-12-09	Πολυμερη βασιζομενα σε κυκλοδεξτρινη για χορηγηση των θεραπευτικων μεσων που ειναι ομοιοπολικως δεσμευμενα σε αυτα
EA200601160A1 (ru)	2006-12-29	2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
CY1105953T1 (el)	2011-04-06	Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
PT1263724E (pt)	2005-09-30	Novos compostos
DE60305484D1 (de)	2006-06-29	Verbindungen und deren verwendung als 5-ht inhibitore
BR0307508A (pt)	2004-12-07	Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DE602004019405D1 (de)	2009-03-26	Pharmazeutische zubereitungen
SE0102055D0 (sv)	2001-06-08	New Compounds
HUP0103203A2 (hu)	2002-01-28	Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
EP1379508A4 (de)	2005-12-28	N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen
WO2006073430A3 (en)	2006-12-07	Therapeutic delivery system comprising a high molecular weight peg-like compound
GEP20043313B (en)	2004-03-10	Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility
IT1272990B (it)	1997-07-01	"composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione".